ERBB3 and cancer: Its sensitivity analysis suggested inhibition of ligand binding to ErbB3 (also known as HER3) as a more successful approach in cancers associated with ligand-induced stimulation of ErbB-PI3K signaling mediated by combinatorial receptor activation.